Oral etoposide combined with oral arsenic plus retinoic acid for two cases with newly diagnosed high-risk acute promyelocytic leukemia during COVID19 pandemic
Acute promyelocytic leukemia (APL) is a highly curable hematology malignancy. The major factor influence prognosis of APL is early deaths (ED) during the course of induction therapy, especially in high-risk APL. Therefore, effective reduction of white blood cells and correction of coagulation abnorm...
Main Authors: | Sheng-ye Lu, Li Wen-jing, Rui Lou, Rui Ma, Ji-hong Zhu, Hao Jiang, Prof., MD. |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-01-01
|
Series: | Leukemia Research Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S221304892100025X |
Similar Items
-
Early Death and Survival of Patients With Acute Promyelocytic Leukemia in ATRA Plus Arsenic Era: A Population-Based Study
by: Hong-Hu Zhu, et al.
Published: (2021-11-01) -
Availability of all-trans retinoic acid and support systems for management of acute promyelocytic leukemia in Michigan and Louisiana, USA
by: Sheldon L. Bolds, et al.
Published: (2019-05-01) -
Acute Promyelocytic Leukemia and Brugada Syndrome: A Report on the Safety of Arsenic Trioxide/All-Trans-Retinoic Acid Therapy
by: Giorgio Rosati, et al.
Published: (2023-07-01) -
On arsenic trioxide in the clinical treatment of acute promyelocytic leukemia
by: Peng Zhang
Published: (2017-01-01) -
Investigation of fibrinogen in early bleeding of patients with newly diagnosed acute promyelocytic leukemia
by: Tiantian Chu, et al.
Published: (2021-07-01)